COMPANY:

Eone Diagnomics Genome Center

"Molecular Health said...that is collaborating with South Korea's Eone-Diagnomics Genome Center (EDGC) to create a combined offering for precision oncology testing. Specifically, the companies are pairing Molecular Health’s MH Guide software and EDGC’s OncoCatch-CDx assay, which analyzes circulating tumor DNA using next-generation sequencing in-house bioinformatics...Under the partnership with Molecular Health, EDGC will utilize that firm's analysis software, which automatically identifies genetic variants that are relevant for the treatment of cancer patients, to support reporting of OncoCatch-CDx results to ordering clinicians."

"The Korean genetic sequencing firm Eone Diagnomics Genome Center (EDGC) has launched an official brand for its advanced early cancer detection technology, paving the way for exports of the service to enter markets in and outside the country. The company based in Incheon's Songdo held a webinar on May 23 to launch ONCOCATCH, a liquid biopsy-based technology...The company aims to introduce the early cancer detection health service to Korea as early as late 2022 following the ministry's approval for commercialization."